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embolism (FOCUS) study will prospectively enroll and sys-
tematically follow, over a 2-year period and with a standard-
ized comprehensive program of clinical, echocardiographic, 
functional and laboratory testing, a large multicenter pro-
spective cohort of 1000 unselected patients (all-comers) 
with acute symptomatic PE. FOCUS will possess adequate 
power to provide answers to relevant remaining questions 
regarding the patients’ long-term morbidity and mortality, 
and the temporal pattern of post-PE abnormalities. It will 
hopefully provide evidence for future guideline recommen-
dations regarding the selection of patients for long-term fol-
low-up after PE, the modalities which this follow-up should 
include, and the findings that should be interpreted as indi-
cating progressive functional and hemodynamic post-PE 
impairment, or the development of CTEPH.
Keywords Pulmonary embolism · Chronic 
thromboembolic pulmonary hypertension · Functional 
impairment · Quality of life · Cohort study · Follow-up
Abstract Acute pulmonary embolism (PE) is a frequent 
cause of death and serious disability. The risk of PE-asso-
ciated mortality and morbidity extends far beyond the acute 
phase of the disease. In earlier follow-up studies, as many 
as 30 % of the patients died during a follow-up period of up 
to 3 years, and up to 50 % of patients continued to complain 
of dyspnea and/or poor physical performance 6 months to 
3 years after the index event. The most feared ‘late sequela’ 
of PE is chronic thromboembolic pulmonary hypertension 
(CTEPH), the true incidence of which remains obscure due 
to the large margin of error in the rates reported by mostly 
small, single-center studies. Moreover, the functional and 
hemodynamic changes corresponding to early, possibly 
reversible stages of CTEPH, have not been systematically 
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comparison, only 8.7 % of patients without PE died during 
the same study period [9]. Of note, there are no recent large 
multicenter cohort studies to provide contemporary, prospec-
tive data on long-term survival rates after PE.
Understanding and, as the following step, predicting the 
clinical course of a patient after acute PE is a far more complex 
task than answering the ‘dead or alive’ question. The available 
data from the follow-up of retrospectively identified patients, 
or from prospective studies of relatively small single-center 
cohorts (reviewed in [10]), suggest that more than 50 % of 
patients continue to complain of dyspnea and/or poor physi-
cal performance 6 months to 3 years after the index event, and 
up to 75 % perceive their own health status as being worse 
than before the acute PE episode. If confirmed in adequately 
powered follow-up studies, these numbers could be translated 
into a substantial clinical impact and socio-economic burden 
imposed by PE over the long term, far beyond that already 
acknowledged for the acute phase of the disease [11, 12]. At the 
far end of the severity spectrum of ‘late PE sequelae’ is a life-
threatening disease termed chronic thromboembolic pulmo-
nary hypertension (CTEPH). This progressive vasculopathy is 
thought to result from incomplete resolution of single or recur-
rent pulmonary emboli arising from sites of venous thrombosis 
[1, 13]. Although the diagnosis and management of CTEPH 
have made progress in recent years [14, 15], its true incidence 
and temporal pattern of development following an episode of 
acute PE remain obscure. The large margin of error in reported 
Unanswered questions after the acute phase of PE: 
the need for a large multicenter cohort study
Acute pulmonary embolism (PE) is a frequent cause of 
death and serious disability [1]. In an epidemiological model 
derived from six European countries, the estimated num-
ber of fatalities related to venous thromboembolism (VTE) 
amounted to 370,000, or 12 % of all deaths [2]. The risk of 
an adverse outcome during the acute phase varies widely 
depending on the clinical severity and the presence of right 
ventricular dysfunction at presentation [3], with early (30-
day) mortality rates ranging from as low as 0.5 % in hemo-
dynamically stable, ‘low-risk’ patients, to over 20 % in those 
presenting with cardiogenic shock [4]. Moreover, and impor-
tantly, the risk to die or develop persistent serious disabil-
ity extends far beyond the acute phase of PE [5]. In earlier 
follow-up studies, as many as 25 % of the patients did not 
survive the first year after diagnosis, with the majority of 
deaths being related to underlying conditions such as can-
cer or chronic heart disease [6–8]. Consistently with these 
data, a cohort study of 866 patients who were retrospectively 
identified as having suffered acute PE (unprovoked in 308 
patients; provoked in 558 patients), reported that 30 % of 
the study population died over a median follow-up period 
of 3.3 years [9]. Of 259 recorded deaths in that study, 110 
were due to malignancy, 67 to recurrent PE, 30 to other car-
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included in FOCUS on the basis of the eligibility criteria 
listed in Table 1. FOCUS explicitly aims to enroll ‘all-
comers’ with PE, irrespective of the clinical severity, evi-
dence of right ventricular dysfunction, or size or extent of 
pulmonary emboli. The primary objective is to determine 
the cumulative incidence of, (1) CTEPH, and (2) persist-
ing or progressive functional and/or hemodynamic post-
PE impairment (PPEI) over a 2-year follow-up period 
after an index episode of acute symptomatic PE. Second-
ary objectives are to assess, among others, overall and dis-
ease-specific long-term mortality, the incidence of major 
adverse cardiovascular events (such as acute myocardial 
infarction, stroke, or VTE recurrence), predictors as well 
as indicators of functional/hemodynamic impairment, fatal 
bleeding complications associated with long-term antico-
agulant treatment for VTE, and the patients’ generic and 
disease-specific quality of life.
Patient outcomes
The complete list of primary, secondary, and safety out-
comes of FOCUS is provided in Table 2. Confirmed diag-
nosis of CTEPH during the 2-year follow-up period is 
the first primary outcome. However, as the occurrence of 
CTEPH is expected to be low and the absolute number 
of events small, even with this large patient population, 
PPEI has been defined as a co-primary outcome. This 
incidence rates of CTEPH (between 0.1 and 9.1 % within the 
first 2 years after a symptomatic PE event), is most likely due 
to referral bias, absence of early symptoms, and the difficulty 
in differentiating acute PE from an episode superimposed on 
pre-existing CTEPH [13, 16]. Moreover, and importantly, 
its ‘prodromi’, i.e. the clinical, functional and hemodynamic 
changes corresponding to early, possibly reversible stages of 
developing CTEPH, have not been systematically investigated.
The ongoing follow-up after acute pulmonary embolism 
(FOCUS) study will prospectively enroll and systematically 
follow, over a 2-year period and with a standardized compre-
hensive program of clinical, echocardiographic, functional 
and laboratory testing, a large multicenter prospective cohort 
of unselected patients (all-comers) hospitalized for acute 
symptomatic PE. FOCUS has been designed to possess ade-
quate power which will enable it to provide answers to the 
above relevant remaining questions regarding the patients’ 
long-term morbidity and mortality after PE. It should thus 
be able to provide evidence for future guideline recommen-
dations on which patients should be selected for long-term 
follow-up after PE, and possibly for ‘CTEPH screening’, 
and which modalities this follow-up should include.
Study population and objectives of FOCUS
A total of 1000 consecutive patients with acute symp-
tomatic, objectively diagnosed PE will be prospectively 
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Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
Objectively confirmed diagnosis of acute symptomatic PE by CTPA,  
V/Q lung scan, or invasive selective pulmonary angiography, according  
to established diagnostic criteria, with or without symptomatic DVT
Patients in whom the diagnosis of PE is an asymptomatic 
incidental finding during diagnostic work-up for another 
disease
Age ≥18 years Patients with previously diagnosed CTEPH
Written informed consent obtained before enrollment Previous enrollment in this study
CTEPH chronic thromboembolic pulmonary hypertension, CTPA computed tomographic pulmonary angiography, DVT deep vein thrombosis, 
PE pulmonary embolism, V/Q ventilation-perfusion
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hypertension and chronic thromboembolic disease [18, 
19], and (3) the risk assessment of pulmonary (arterial) 
hypertension at follow-up visits as recommended in the 
2009 [20] and recently updated [14] guidelines of the 
European Society of Cardiology and the European Respi-
ratory Society. A detailed overview of the assessment and 
classification of individual indicators of PPEI ((a) and (b) 
parameters) is provided in Table 3.
All outcomes will be adjudicated by an independent 
Clinical Events Committee (CEC).
approach, which is explained in the statistical analysis 
section below, has its rationale in the assumption that 
persisting or progressive functional and/or hemodynamic 
impairment after acute PE is an early indicator of, and 
in statistical terms a ‘necessary condition’ for, the subse-
quent development of CTEPH. PPEI was defined by the 
FOCUS steering committee based on (and extrapolated 
from), (1) previously proposed prognostic criteria for pul-
monary hypertension [17], (2) practical guides to cardio-
pulmonary exercise testing for evaluation of pulmonary 
Co-primary outcomesa
(1) Confirmed diagnosis of CTEPH at any time during the 2-year follow-up
(2) Post-PE impairment, defined by deterioration (compared to the findings at discharge, or to the previous follow-up visit) by at least one 
category, or persistence of the greatest severity category, in ≥1 of ‘a’ parameters plus deterioration by at least one category, or persistence of 
the greatest severity category, in ≥1 of ‘b’ parameters
(a) Echocardiographic parameters of pulmonary hypertension and/or  
RV dysfunctionb
(b) Clinical, functional and laboratory parameters of RV failureb
(a1) RV basal diameter (D1) (b1) New appearance of symptoms or progression of existing 
symptoms
(a2) RA end-systolic area (b2) Clinical evidence of RV failure
(a3) TAPSE (b3) Syncope
(a4) LV eccentricity index (b4) WHO functional class
(a5) Estimated RA pressure (b5) Six-minute walking distance
(a6) Systolic TR jet velocity (b6) BNP or NT-proBNP plasma levels
(a7) Pericardial effusion (b7) Cardiopulmonary exercise testing
Secondary outcomes
(1) Overall and disease-specific mortality during follow-up
(2) Symptomatic recurrence of DVT or PE
(3) Rehospitalization for reasons related to VTE, CTEPH, or complications of their treatment
(4) New diagnosis of cancer
(5) Acute myocardial infarction
(6) Stroke
(7) Functional limitation (peak O2 consumption and systolic blood pressure on cardiorespiratory exercise testing; six-minute walking distance 
and Borg dyspnea index)
(8) Evidence of pulmonary hypertension/right ventricular dysfunction on echocardiography
(9) Evidence of pulmonary vascular abnormalities on cardiopulmonary exercise testingc
(10) Generic and disease-specific quality of life using the EQ-5D and the PEmb-QoL questionnaires
Safety outcomes
(1) Major bleeding during hospitalization for the index event, based on the ISTH definition [21]
(2) Fatal bleeding at any time during follow-up
BNP brain natriuretic peptide, CTEPH chronic thromboembolic pulmonary hypertension, EQ-5D Euro Quality of life five dimensions (ques-
tionnaire), ISTH International Society on Thrombosis and Haemostasis, NT-proBNP N-terminal pro-brain natriuretic peptide, PE pulmonary 
embolism, PEmb-QoL Pulmonary Embolism Quality of Life (questionnaire), RA right atrial, RV right ventricular, TAPSE tricuspid annular 
plane systolic excursion, TR tricuspid regurgitation, VTE venous thromboembolism, WHO World Health Organization
aSee statistical analysis for details
bSee Table 3 for severity classification of individual findings and parameters
cIndicated by at least one of the following: PETCO2 at AT (end-tidal partial carbon dioxide pressure at anaerobic threshold) <31.33 mmHg; 
P(a-ET)CO2 >5.18 mmHg; EQ O2 (oxygen ventilatory equivalent) >30.5; EQ CO2 (carbon dioxide ventilatory equivalent) >35.5; VE/VCO2 slope 
(ventilator efficiency for carbon dioxide) >37.5; P(A-a) O2 (alveolar–arterial oxygen gradient) >36.97 mm [22]
Table 2 Primary, secondary, and safety outcomes
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Biobanking substudy: the FOCUS BioSeq project
A multicenter biobanking substudy ‘Biochemical and 
Genetic Biomarkers in Sequelae of Acute Pulmonary Embo-
lism Study (FOCUS BioSeq)’ is being conducted within the 
FOCUS cohort. Currently, a number of biomarkers have a 
place in PE management; most of them, including d-dimers, 
cardiac troponins, and natriuretic peptides, are used in the 
differential diagnosis or risk stratification of acute PE [1]. On 
the other hand, a systematic biochemical and genetic charac-
terization of PE survivors over the long term is missing in the 
literature. Thus, the primary objective of the FOCUS BioSeq 
substudy is to identify and evaluate molecular and genetic 
markers for late sequelae of acute PE. Further objectives are 
to evaluate novel and established biomarkers for cost effec-
tiveness and suitability in long-term management strategies, 
and as predictors of the response to pharmacotherapy.
Study design and flow
FOCUS is a prospective, multicenter, observational cohort 
study. The study protocol does not dictate any diagnostic 
or therapeutic interventions. On the other hand, the partici-
pating sites, which are high-volume centers with a long-
standing experience in PE and pulmonary hypertension 
management, have harmonized their existing follow-up 
protocols and agreed that they will adhere to the follow-up 
schedule and workup presented in Table 4, which they con-
sider as ‘best medical care’.
Detailed demographic and clinical data, diagnostic and 
therapeutic procedures, and outcome variables are recorded 
in an electronic case report form (eCRF). Regular follow-
up visits are performed on discharge, and at 3, 12, and 
24 months, as part of the best medical care standard at the 
participating centers.
Table 4 Data collection schedule
Variable In-hospital Follow-up
Enrollment Discharge 3 months 12 months 24 months
Medical history x
Demographic dataa x
Clinical examinationb x x x x
Imaging (PE diagnosis) x
Echocardiography x x x x x
Cardiopulmonary exercise testing x x x
Laboratory diagnostic and safety testsc x x x x x
Pharmacological treatment x x x x x
Hemodynamic collapse x x x x x
Survival status x x x x
Rehospitalization x x x
Stroke x x x x
Symptomatic recurrent DVT/PE x x x x
Bleeding events x x x x
Functional statusd x x x
Diagnostic work-up for CTEPHe x x x
Generic quality of lifef x x x
Disease-specific quality of lifeg x x x
CTEPH chronic thromboembolic pulmonary hypertension, DVT deep vein thrombosis, PE pulmonary embolism
aDate of birth, gender, height, weight
bPresentation and symptomatology, vital signs; 12-lead ECG
cSerum creatinine, creatinine clearance [MDRD-estimate], TSH, O2-saturation [pulse oximetry], hematocrit, thrombocytes, leucocytes, aPTT, 
PT, INR, troponin T or I, NT-pro-BNP, BNP, CRP, d-dimer
dWHO functional class, Borg dyspnea index
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Collected and purified DNA will be used for array-based 
genome-wide investigations aiming at discovering new 
genetic loci (further investigated by sequencing methods) 
which may predict the future clinical course of the disease 
or the response to drugs. Extracted RNA specimen like 
cellular mRNA, small non coding RNA or miRNA can be 
used for sequence probe based differential gene expression 
investigations. Epigenetic modifications on DNA samples 
or newly identified and known protein biomarkers at defined 
time points or in serial measurements from the follow-up 
assessment might be of prognostic relevance.
Sample size calculation and statistical analysis
For sample size calculation, we assumed that the annual 
incidence rate of CTEPH in unselected patients who have 
suffered an episode of acute symptomatic PE (either pro-
voked or unprovoked) is at least five times higher than the 
very low rate of 0.16 per 100 patients per year reported in 
one of the largest cohorts published to date [25], i.e. 0.8 per 
100 patients per year. We further assumed that overall death 
rates and case-mix (high risk versus intermediate-risk ver-
sus low risk PE) will be similar to that previous study [25], 
and that there will be a ≤5 % loss-to-follow-up per year in 
addition to the administrative censoring and deaths. Follow-
ing these assumptions, the cumulative incidence of CTEPH 
at 2 years is expected to amount to 1.3 %. In this case, our 
simulations indicate that a study population of 1000 patients 
To achieve these goals, a decentralized and pseudony-
mized sample collection with centrifugal (standardized) 
preprocessing of plasma, serum and urine with short-term 
storage at −80 °C is being implemented in the participating 
study centers. For sample shipment to the central biobank-
ing facility, pseudonyms and temperature control are main-
tained. On arrival, single sample aliquots are indexed for 
retrieval. Nucleic acids (DNA and RNA) are centrally iso-
lated and quantity- and quality-controlled. Shipped, indexed 
and quality-controlled biomaterials are subsequently long-
term stored in a centralized, 2-D barcoded and mirrored 
biobank at −80 °C. The following biomaterial specimens 
are collected in sufficient volumes for biomarker charac-
terization and progression analysis in baseline and follow-
up investigations: EDTA plasma, citrated plasma (3.2 %), 
serum, whole blood DNA and whole blood RNA (see 
Supplementary Table 1). Samples are collected and pro-
cessed according to standard operating procedures (SOP). 
The FOCUS BioSeq biobanking procedures are illustrated 
in Fig. 1. Collection of biomaterial and optionally genetic 
examinations or exchange of biomaterial and data with col-
laboration partners are carried out after informed written 
consent has been provided by the study participant.
From the processed specimens, various biomarkers will 
be determined; a special focus will be put on biomarkers 
with known or expected relevance for the (pathophysiol-
ogy of) circulation, hemostasis, inflammation, immunity, 
and kidney disease. High-throughput screening approaches 
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All findings, including clinical and laboratory data, are 
documented in individual medical records and in the eCRF. 
During entry of pseudonymized data, integrity checks help 
to minimize entry failures; any missing data or inconsisten-
cies are reported back to the respective site and clarified 
by the responsible investigator. Regular monitoring is per-
formed by personal visits from clinical monitors.
In case of withdrawal of a subject, the reason is docu-
mented and the patient is asked to consent to visit the clinic 
or a telephone interview in order to obtain as complete data as 
possible. Civil registers will be accessed or the patient´s fam-
ily physician contacted if a personal contact is not possible.
Innovative features and expected impact of 
FOCUS
Existing data suggest that incomplete thrombus resolution 
as well as persisting hemodynamic abnormalities and func-
tional limitation over the long term occur quite frequently 
after acute PE. For example, between 30 and 52 % of the 
patients who survive the acute phase have been reported to 
have evidence of residual perfusion defects for at least 1 year 
after the acute event [26–29]; furthermore, the proportion of 
patients with some degree of persistent pulmonary hyper-
tension after acute PE ranged between 40 and 69 % [30, 
31]. However, these data are to be interpreted with caution, 
since the single-center cohort studies conducted thus far 
included rather small numbers of patients, the echocardio-
graphic parameters used to assess the hemodynamic status 
post PE did not rigorously follow the standards proposed by 
scientific societies [32], and a correlation of ultrasound or 
thrombus imaging findings with the severity of the patients’ 
residual symptoms or the degree of functional limitation at 
follow-up could not be established [33]. These limitations 
unavoidably generate a high degree of uncertainty in esti-
mating and predicting late outcomes after PE, more spe-
cifically the risk of developing CTEPH [5] as well as the 
entirety of persisting or progressive abnormalities belong-
ing to the so-called ‘post-PE syndrome’ [10]. In this con-
text, it also needs to be mentioned that some patients who 
have had PE may present with chronic symptomatic disease, 
which is morphologically indistinguishable from CTEPH 
but associated with normal pulmonary hemodynamics at 
rest (on echocardiography and right heart catheterization). 
Although these patients are also considered to have CTEPH 
and are managed accordingly, the pathophysiology of this 
‘chronic thromboembolic pulmonary vascular disease’ 
remains obscure, and an exact definition and appropriate 
terminology is still lacking. In view of all these uncertain-
ties, even the most recent guidelines are unable to provide 
clear recommendations on who, how often, and with what 
modalities should be followed after acute PE [1, 14].
will provide roughly 90 % power to reject the H0 hypothesis 
that the cumulative incidence of CTEPH at 2-year follow-
up is 0.27 % (the cumulative incidence corresponding to the 
rate reported in [25]).
For a subgroup with an expected size of about 500 
patients with unprovoked PE, i.e. an index PE event in the 
absence of reversible predisposing factors, an exploratory 
analysis will be performed. In this analysis, a power of more 
than 80 % can still be achieved to reject the H0 hypothesis 
that the cumulative incidence of CTEPH at 2-year follow-
up is 0.27 %, if the hazard in the subgroup is at least six 
times higher than that previously reported for the unselected 
PE population [9, 25].
All enrolled patients will be included in the statistical 
analysis. Hierarchical testing will be used for the two co-pri-
mary outcomes, CTEPH and PPEI, assuming that all patients 
will present with PPEI before or at the time of the diagnosis 
of CTEPH. Therefore, we will first test whether the cumu-
lative incidence of PPEI is significantly higher than 0.27 % 
at 2 years, and, if this is the case, whether the cumulative 
incidence for CTEPH also differs from the same threshold. 
The overall level of significance will be set to α = 0.05. Both 
tests will have a local power of approximately 90 %. Testing 
will be performed by checking whether the 95 % confidence 
interval of the 2-year Aalen-Johansen estimate of the cumu-
lative incidence function (CIF) contains the value 0.27 %.
For the analysis of the primary outcome, it is assumed 
that CTEPH and PPEI can be considered independent of 
possible deaths during follow-up (e.g., mortality associated 
with cancer, myocardial infarction or stroke); if the cause of 
death is not independent from PPEI, the analysis for the pri-
mary outcome assumes that CTEPH or PPEI is always diag-
nosed before death. While these assumptions can reasonably 
be expected to hold true for PPEI, they might be less robust 
for CTEPH. Therefore, this latter point will be addressed by 
sensitivity analyses. The planned secondary and sensitivity 
analyses are listed in the Supplementary Material.
Ethical aspects and data handling
The FOCUS study has been approved by the independent 
ethics committee at each participating site; it is being car-
ried out in accordance with all local legal and regulatory 
requirements. All subjects must provide written informed 
consent to participate in the study, and a separate informed 
consent form is obtained for blood sampling and biodata 
banking. The study has been registered in the German 
Clinical Trials registry (http://www.germanctr.de; identifier: 
DRKS00005939).
As already mentioned, the study protocol does not dictate 
any diagnostic or therapeutic interventions; patients enrolled 
in FOCUS are treated according to current guidelines [1]. 
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